Importantly, we demonstrate that silencing SEMA3C inhibits the MAPK and AKT signaling pathways, promotes apoptosis, and suppresses the growth of both tamoxifen-sensitive and resistant ER+ breast cancer cells. The gene discussed is ESR1; the disease is breast carcinoma.